Brokerages Set Generate Biomedicines Inc (NASDAQ:GENB) Price Target at $25.40

Posted by George Bondi on Aug 28th, 2026

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $25.40.

A number of equities analysts have recently issued reports on GENB shares. HC Wainwright upped their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Morgan Stanley boosted their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings started coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They issued a “sell (d)” rating for the company.

Check Out Our Latest Analysis on GENB

Generate Biomedicines Stock Performance

GENB stock opened at $15.77 on Friday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $22.67. The firm has a 50 day moving average of $15.26. The company has a market cap of $2.02 billion and a price-to-earnings ratio of -9.92.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. On average, research analysts expect that Generate Biomedicines will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Generate Biomedicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new position in shares of Generate Biomedicines in the 2nd quarter valued at about $96,000. Susquehanna International Group LLP bought a new stake in shares of Generate Biomedicines during the second quarter worth approximately $196,000. AXQ Capital LP acquired a new position in Generate Biomedicines in the second quarter valued at approximately $218,000. Bank of New York Mellon Corp acquired a new position in Generate Biomedicines in the second quarter valued at approximately $967,000. Finally, Braidwell LP bought a new position in Generate Biomedicines in the second quarter valued at approximately $55,398,000.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.